OncoMatch/Clinical Trials/NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Is NCT07644559 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies multiple treatments including VS-7375 and cetuximab for pancreatic ductal adenocarcinoma (pdac).
Treatment: VS-7375 · cetuximab — This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12d
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
Excluded: KRAS other documented co-existing common ras mutation(s)
Have any other documented co-existing common RAS mutation(s)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: direct RAS inhibitor
Receipt of prior direct RAS inhibitor
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START- Los Angeles · Los Angeles, California
- Moffitt Cancer Center · Tampa, Florida
- Johns Hopkins University · Baltimore, Maryland
- START Midwest · Grand Rapids, Michigan
- Washington University · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07644559 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior direct RAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Are patients with KRAS alterations eligible?
No. KRAS other documented co-existing common ras mutation(s) is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages